About Us
ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. We have four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. Our other clinical-stage products include collaborative programs for chronic pain and glaucoma with Allergan, Inc., and a collaborative program for schizophrenia with Meiji Seika Pharma Co., Ltd.
All of ACADIA’s product candidates are small molecules that emanate from discoveries made using our proprietary drug discovery platform. We have assembled a strong team of industry-experienced executives to lead the development of our product candidates and we complement this team with a group of world-class scientific and clinical advisors.
back to top